Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer

J. Juracek, M. Madrzyk, M. Stanik, M. Ruckova, K. Trachtova, H. Malcikova, E. Lzicarova, DA. Barth, M. Pichler, O. Slaby

. 2023 ; 83 (4) : 340-351. [pub] 20221208

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004023

BACKGROUND: Prostate cancer (PCa) is a heterogeneous malignancy with high variability in clinical course. Insufficient stratification according to the aggressiveness at the time of diagnosis causes unnecessary or delayed treatment. Current stratification systems are not effective enough because they are based on clinical, surgical or biochemical parameters, but do not take into account molecular factors driving PCa cancerogenesis. MicroRNAs (miRNAs) are important players in molecular pathogenesis of PCa and could serve as valuable biomarkers for the assessment of disease aggressiveness and its prognosis. METHODS: In the study, in total, 280 PCa patients were enrolled. The miRNA expression profiles were analyzed in FFPE PCa tissue using the miRCURY LNA miRNA PCR System. The expression levels of candidate miRNAs were further verified by two-level validation using the RT-qPCR method and evaluated in relation to PCa stratification reflecting the disease aggressiveness. RESULTS: MiRNA profiling revealed 172 miRNAs dysregulated between aggressive (ISUP 3-5) and indolent PCa (ISUP 1) (p < 0.05). In the training and validation cohort, miR-15b-5p and miR-106b-5p were confirmed to be significantly upregulated in tissue of aggressive PCa when their level was associated with disease aggressiveness. Furthermore, we established a prognostic score combining the level of miR-15b-5p and miR-106b-5p with serum PSA level, which discriminated indolent PCa from an aggressive form with even higher analytical parameters (AUC being 0.9338 in the training set and 0.8014 in the validation set, respectively). The score was also associated with 5-year biochemical progression-free survival (bPFS) of PCa patients. CONCLUSIONS: We identified a miRNA expression pattern associated with disease aggressiveness in prostate cancer patients. These miRNAs may be of biological interest as the focus can be also set on their specific role within the molecular pathology and the molecular mechanism that underlies the aggressivity of prostate cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004023
003      
CZ-PrNML
005      
20230425141037.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24466 $2 doi
035    __
$a (PubMed)36478451
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Juracek, Jaroslav $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000199452530 $7 xx0165783
245    12
$a A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer / $c J. Juracek, M. Madrzyk, M. Stanik, M. Ruckova, K. Trachtova, H. Malcikova, E. Lzicarova, DA. Barth, M. Pichler, O. Slaby
520    9_
$a BACKGROUND: Prostate cancer (PCa) is a heterogeneous malignancy with high variability in clinical course. Insufficient stratification according to the aggressiveness at the time of diagnosis causes unnecessary or delayed treatment. Current stratification systems are not effective enough because they are based on clinical, surgical or biochemical parameters, but do not take into account molecular factors driving PCa cancerogenesis. MicroRNAs (miRNAs) are important players in molecular pathogenesis of PCa and could serve as valuable biomarkers for the assessment of disease aggressiveness and its prognosis. METHODS: In the study, in total, 280 PCa patients were enrolled. The miRNA expression profiles were analyzed in FFPE PCa tissue using the miRCURY LNA miRNA PCR System. The expression levels of candidate miRNAs were further verified by two-level validation using the RT-qPCR method and evaluated in relation to PCa stratification reflecting the disease aggressiveness. RESULTS: MiRNA profiling revealed 172 miRNAs dysregulated between aggressive (ISUP 3-5) and indolent PCa (ISUP 1) (p < 0.05). In the training and validation cohort, miR-15b-5p and miR-106b-5p were confirmed to be significantly upregulated in tissue of aggressive PCa when their level was associated with disease aggressiveness. Furthermore, we established a prognostic score combining the level of miR-15b-5p and miR-106b-5p with serum PSA level, which discriminated indolent PCa from an aggressive form with even higher analytical parameters (AUC being 0.9338 in the training set and 0.8014 in the validation set, respectively). The score was also associated with 5-year biochemical progression-free survival (bPFS) of PCa patients. CONCLUSIONS: We identified a miRNA expression pattern associated with disease aggressiveness in prostate cancer patients. These miRNAs may be of biological interest as the focus can be also set on their specific role within the molecular pathology and the molecular mechanism that underlies the aggressivity of prostate cancer.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x metabolismus $7 D035683
650    12
$a nádory prostaty $x patologie $7 D011471
650    _2
$a prognóza $7 D011379
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a regulace genové exprese u nádorů $7 D015972
655    _2
$a časopisecké články $7 D016428
700    1_
$a Madrzyk, Marie $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000233071230
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $1 https://orcid.org/000000025123024X
700    1_
$a Ruckova, Michaela $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000156616072
700    1_
$a Trachtova, Karolina $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Malcikova, Hana $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Lzicarova, Eva $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Barth, Dominik A $u Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria
700    1_
$a Pichler, Martin $u Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria $1 https://orcid.org/0000000287019462
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284500584 $7 js20030220015
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 83, č. 4 (2023), s. 340-351
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36478451 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141033 $b ABA008
999    __
$a ok $b bmc $g 1924589 $s 1190232
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 83 $c 4 $d 340-351 $e 20221208 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20230418
Back

Find record

Citation metrics

Archiving options